These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 1438709)

  • 1. Protection against metastasis of radiation-induced thymic lymphosarcoma and weight loss in C57Bl/6NCr1BR mice by an autoclave-resistant factor present in soybeans.
    Evans SM; Van Winkle T; Szuhaj B; Michel KE; Kennedy AR
    Radiat Res; 1992 Nov; 132(2):259-62. PubMed ID: 1438709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer prevention by protease inhibitors.
    Kennedy AR
    Prev Med; 1993 Sep; 22(5):796-811. PubMed ID: 8234219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate.
    Kennedy AR; Szuhaj BF; Newberne PM; Billings PC
    Nutr Cancer; 1993; 19(3):281-302. PubMed ID: 8346077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies related to the potential antigenicity of the Bowman-Birk inhibitor, an anticarcinogenic protease inhibitor isolated from soybeans.
    Maki PA; Paterson Y; Kennedy AR
    Nutr Cancer; 1994; 22(2):185-93. PubMed ID: 14502847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Bowman-Birk inhibitor and anti-Bowman-Birk inhibitor antibodies in sera of humans and animals treated with Bowman-Birk inhibitor concentrate.
    Wan XS; Serota DG; Ware JH; Crowell JA; Kennedy AR
    Nutr Cancer; 2002; 43(2):167-73. PubMed ID: 12588697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment.
    Armstrong WB; Wan XS; Kennedy AR; Taylor TH; Meyskens FL
    Laryngoscope; 2003 Oct; 113(10):1687-702. PubMed ID: 14520092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial.
    Armstrong WB; Kennedy AR; Wan XS; Taylor TH; Nguyen QA; Jensen J; Thompson W; Lagerberg W; Meyskens FL
    Clin Cancer Res; 2000 Dec; 6(12):4684-91. PubMed ID: 11156220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the Bowman-Birk protease inhibitor on survival of fibroblasts and cancer cells exposed to radiation and cis-platinum.
    Kennedy CW; Donahue JJ; Wan XS
    Nutr Cancer; 1996; 26(2):209-17. PubMed ID: 8875558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor.
    St Clair WH; Billings PC; Carew JA; Keller-McGandy C; Newberne P; Kennedy AR
    Cancer Res; 1990 Feb; 50(3):580-6. PubMed ID: 2297699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of connexin 43 by Bowman-Birk protease inhibitor in M5076 bearing mice.
    Suzuki K; Yano T; Sadzuka Y; Sugiyama T; Seki T; Asano R
    Oncol Rep; 2005 Jun; 13(6):1247-50. PubMed ID: 15870950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenicity evaluations of chemopreventive soy components in p53((+/-)) (p53 knockout) mice.
    Johnson WD; Dooley L; Morrissey RL; Arp L; Kapetanovic I; Crowell JA; McCormick DL
    Int J Toxicol; 2006; 25(3):219-28. PubMed ID: 16717037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of carcinogenesis in the intestines of min mice by the soybean-derived Bowman-Birk inhibitor.
    Kennedy AR; Beazer-Barclay Y; Kinzler KW; Newberne PM
    Cancer Res; 1996 Feb; 56(4):679-82. PubMed ID: 8630994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imbibition of soybean seeds in warm water results in the release of copious amounts of Bowman-Birk protease inhibitor, a putative anticarcinogenic agent.
    Palavalli MH; Natarajan SS; Wang TT; Krishnan HB
    J Agric Food Chem; 2012 Mar; 60(12):3135-43. PubMed ID: 22372424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bowman-Birk soybean protease inhibitor as an anticarcinogen.
    Yavelow J; Finlay TH; Kennedy AR; Troll W
    Cancer Res; 1983 May; 43(5 Suppl):2454s-2459s. PubMed ID: 6682011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cationized Bowman-Birk protease inhibitor as a targeted cancer chemopreventive agent.
    Ekrami H; Kennedy AR; Witschi H; Shen WC
    J Drug Target; 1993; 1(1):41-9. PubMed ID: 8069543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia.
    Armstrong WB; Kennedy AR; Wan XS; Atiba J; McLaren CE; Meyskens FL
    Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):43-7. PubMed ID: 10667462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis.
    Ware JH; Wan XS; Newberne P; Kennedy AR
    Dig Dis Sci; 1999 May; 44(5):986-90. PubMed ID: 10235608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.